Research during the coming years may provide answers to whether or not glucagon agonism/antagonism will reach clinical application for treatment of metabolic diseases such as obesity and type 2 diabetes [9]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.